strengthen client privacy and confidentiality, the following DVHT client-level indicators have been removed: Type of Intake, Date of Birth, Disability Status, Services Requested at Intake, Benefits Requested at Intake, and Trafficker Relationship to Victim.

Respondents: DVHT Program Grant Recipients and Clients of those programs, specifically DVHT–SO and VHT–NC funding recipients.

ANNUAL BURDEN ESTIMATES

Instrument	Total number of respondents	Total number of responses per respondent	Average burden hours per response	Total burden hours	Annual burden hours
Client Characteristics and Program Entry	1700	1	0.75	1,275	425
Client Case Closure	1700	1	0.167	283.9	94.6
Barriers to Service Delivery and Monitoring	35	4	0.167	23.4	7.8
Client Service Use and Delivery	1700	1	0.25	425	141.7
Victim Outreach	35	4	0.3	42	14
Training	35	4	0.5	70	23.3
Subrecipient Enrollment	35	3	0.167	17.5	5.8

Estimated Total Annual Burden Hours: 712.2.

Comments: The Department specifically requests comments on (a) whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Consideration will be given to comments and suggestions submitted within 60 days of this publication.

(Authority: 22 U.S.C. 7105)

Mary B. Jones,

ACF/OPRE Certifying Officer.

[FR Doc. 2022–16066 Filed 7–26–22; 8:45 am]

BILLING CODE 4184–47–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

Proposed Information Collection Activity; Provision of Child Support Services in IV–D Cases Under the Hague Child Support Convention (OMB #0970–0488)

AGENCY: Office of Child Support Enforcement, Administration for Children and Families, Department of Health and Human Services.

ACTION: Request for public comments.

SUMMARY: The Office of Child Support Enforcement (OCSE), Administration for Children and Families (ACF), is requesting a three-year extension with proposed revisions to the Hague Child Support Forms (OMB #0970–0488, expiration February 28, 2023). There are two new forms being incorporated.

DATES: *Comments due within 60 days of publication.* In compliance with the requirements of the Paperwork Reduction Act of 1995, ACF is soliciting public comment on the specific aspects of the information collection described above.

ADDRESSES: You can obtain copies of the proposed collection of information and submit comments by emailing *infocollection@acf.hhs.gov*. Identify all requests by the title of the information collection.

SUPPLEMENTARY INFORMATION:

Description: On January 1, 2017, the 2007 Hague Convention on the International Recovery of Child Support and Other Forms of Family Maintenance (the Convention) entered into force for the United States. This multilateral Convention contains groundbreaking provisions that, on a worldwide scale, establish uniform, simple, fast, and inexpensive procedures for the processing of international child support cases. Under the Convention, U.S. states process child support cases with other countries that have ratified the Convention under the requirements of the Convention and Article 7 of the Uniform Interstate Family Support Act (UIFSA 2008). In order to comply with the Convention, the U.S. implements the Convention's case processing forms.

Newly incorporated into this information collection are two additional forms, Request for Specific Measures and Request for Specific Measures—Response, which were approved in June 2022 for use under the Convention. The other forms remain unchanged.

State and federal law require states to use federally approved case processing forms. Section 311(b) of UIFSA 2008, which has been enacted by all 50 states, the District of Columbia, Guam, Puerto Rico, and the Virgin Islands, requires states to use forms mandated by federal law. 45 CFR 303.7 also requires child support programs to use federally approved forms in intergovernmental IV–D cases unless a country has provided alternative forms as a part of its chapter in a Caseworker's Guide to Processing Cases with Foreign Reciprocating Countries.

Respondents: State agencies administering a child support program under title IV–D of the Social Security Act.

ANNUAL BURDEN ESTIMATES

Instrument	Total number of respondents	Total number of responses per respondent	Average burden hours per response	Annual burden hours
Annex I: Transmittal form under Article 12(2)	54	41	1	2,214
Annex II: Acknowledgment form under Article 12(3)	54	81	.5	2,187
Annex A: Application for Recognition or Recognition and Enforcement, including restricted information on the applicant	54	16	.5	432
Annex A: Abstract of Decision	54	4	1	216
Annex A: Statement of Enforceability of Decision	54	16	0.17	147
Annex A: Statement of Proper Notice	54	4	.5	108
Annex A: Status of Application Report—Article 12	54	34	.33	606
Annex B: Application for Enforcement of a Decision Made or Recognized in the Requested State, including restricted information on the applicant	54	17	.5	459
Annex B: Status of Application Report—Article 12	54	33	.33	588
Annex C: Application for Establishment of a Decision, including restricted information on the Applicant	54	4	.5	108
Annex C: Status of Application Report—Article 12	54	8	.33	143
Annex D: Application for Modification of a Decision, including Restricted Information on the Applicant	54	4	.5	108
Annex D: Status of Application Report—Article 12	54	8	.33	143
Annex E: Financial Circumstances Form	54	41	2	4,428
Annex F: Request for Specific Measures—Article 7(1)	54	2	.17	18
Annex F: Request for Specific Measures—Response—Article 7(1)	54	8	.17	73

Estimated Total Annual Burden Hours: 11,978.

Comments: The Department specifically requests comments on (a) whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Consideration will be given to comments and suggestions submitted within 60 days of this publication.

Authority: 42 U.S.C. 654(20) and 666(f).

Mary B. Jones,

ACF/OPRE Certifying Officer.

[FR Doc. 2022–16068 Filed 7–26–22; 8:45 am]

BILLING CODE 4184–41–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2022–N–0995]

Ivax Pharmaceuticals, Inc.; Withdrawal of Approval of an Abbreviated New Drug Application for Chloramphenicol Capsules, 250 Milligrams

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is withdrawing the approval of abbreviated new drug application (ANDA) 062247 for chloramphenicol capsules, 250 milligrams (mg), held by Ivax Pharmaceuticals, Inc. (Ivax). Ivax requested withdrawal of this application and has waived its opportunity for a hearing.

DATES: Approval is withdrawn as of July 27, 2022.

FOR FURTHER INFORMATION CONTACT: Nikki Mueller, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 6280, Silver Spring, MD 20993–0002, 301–796–3601.

SUPPLEMENTARY INFORMATION: On April 28, 1980, FDA approved ANDA 062247 for chloramphenicol capsules, 250 mg, an antibiotic indicated to treat only serious infections for which less potentially dangerous drugs are ineffective or contraindicated. CHLOROMYCETIN (chloramphenicol) Capsules, 250 mg (ANDA 060591), was the basis of submission for Ivax's ANDA 062247 for chloramphenicol capsules, 250 mg. In a **Federal Register** notice dated July 13, 2012 (77 FR 41412), FDA determined under 21 CFR 314.161 that CHLOROMYCETIN (chloramphenicol) Capsules, 250 mg (ANDA 060591), was withdrawn for safety reasons and that additional nonclinical and possibly clinical studies of safety and efficacy would be necessary before CHLOROMYCETIN (chloramphenicol) Capsules, 250 mg, could be considered for reintroduction to the market. The holders of approved applications for chloramphenicol capsules, 250 mg, had ceased marketing of the drug products before July 13, 2012.

On March 29, 2013, Ivax requested that FDA withdraw approval of ANDA 062247 for chloramphenicol capsules, 250 mg. On June 17, 2021, Ivax requested that FDA withdraw approval of ANDA 062247 for chloramphenicol capsules, 250 mg, specifically under § 314.150(d) (21 CFR 314.150(d)) and waived its opportunity for a hearing. For the reasons discussed above, and pursuant to the application holder's request under 314.150(d), approval of ANDA 062247 for chloramphenicol capsules, 250 mg, and all amendments and supplements thereto, is withdrawn under § 314.150(d). Distribution of chloramphenicol capsules, 250 mg, into interstate commerce without an approved application is illegal and subject to regulatory action (see sections 505(a) and 301(d) of the Federal Food,